Orion Pharma
Orionintie 1, 02200 Espoo
P.O.Box 65
Espoo
FIN-02101
Tel: 358-9-4291
Fax: +358-9-429-3815
Website: http://www.orionpharma.com/
7 articles about Orion Pharma
-
While some biopharma companies seek an effective and non-addictive alternative to opioids, others are looking to make opioids themselves safer.
-
Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
1/26/2024
Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208, an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer with and without AR-LBD mutations.
-
Orion Pharmaceuticals Implements Genedata Biologics to Support New Large-Molecule R&D Initiative
9/11/2019
Genedata Biologics to accelerate antibody discovery and streamline R&D operations at Finland’s largest biopharma company
-
Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO
6/5/2018
Tenax Therapeutics, Inc. today announced the Company has selected board member Anthony A. DiTonno to be its next Chief Executive Officer, effective June 1, 2018.
-
Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer's Disease Program
6/29/2012
-
Orion Pharma Selects ChemDiv, Inc. as a Partner in Drug Discovery Services
11/30/2007
-
Orion Pharma's Mixed Results; Abbott Laboratories Shares Drop After Study Of Simdax Disappoints
11/15/2005